Statins are cholesterol-lowering drugs extensively used for primary and secondary prevention of cardiovascular events related to hypercholesterolemia. Because of their capacity to inhibit HMG-CoA reductase, statins also block the production of isoprenoids required for post-translational modification of proteins such as Ras superfamily GTPases, which are master regulators in signaling pathways triggered by surface receptors. As such, statins have pleiotropic effects on many cell types. In the immune system, statins harbor strong anti-inflammatory properties, which result from their capacity to interfere with the activation of proinflammatory cells, including macrophages and endothelial cells. More recently, T-lymphocytes have been identified as cellular targets of statins. Here we shall review recent findings, which document an inhibitory activity of statins on T-cell activation, proliferation, differentiation to Th1 cells and migration across the bloodbrain barrier. The therapeutic perspectives of these findings, based on animal models and ongoing clinical trials, will also be discussed. © 2007 Bentham Science Publishers Ltd.
Ghittoni, R., Lazzerini, P.E., LAGHI PASINI, F., Baldari, C. (2007). T lymphocytes as targets of statins: molecular mechanisms and therapeutic perspectives. INFLAMMATION & ALLERGY - DRUG TARGETS, 6(1), 3-16 [10.2174/187152807780077291].
T lymphocytes as targets of statins: molecular mechanisms and therapeutic perspectives
LAZZERINI P. E.;LAGHI PASINI F.;BALDARI C.
2007-01-01
Abstract
Statins are cholesterol-lowering drugs extensively used for primary and secondary prevention of cardiovascular events related to hypercholesterolemia. Because of their capacity to inhibit HMG-CoA reductase, statins also block the production of isoprenoids required for post-translational modification of proteins such as Ras superfamily GTPases, which are master regulators in signaling pathways triggered by surface receptors. As such, statins have pleiotropic effects on many cell types. In the immune system, statins harbor strong anti-inflammatory properties, which result from their capacity to interfere with the activation of proinflammatory cells, including macrophages and endothelial cells. More recently, T-lymphocytes have been identified as cellular targets of statins. Here we shall review recent findings, which document an inhibitory activity of statins on T-cell activation, proliferation, differentiation to Th1 cells and migration across the bloodbrain barrier. The therapeutic perspectives of these findings, based on animal models and ongoing clinical trials, will also be discussed. © 2007 Bentham Science Publishers Ltd.File | Dimensione | Formato | |
---|---|---|---|
38491_UPLOAD.pdf
non disponibili
Tipologia:
Altro materiale allegato
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
331.73 kB
Formato
Adobe PDF
|
331.73 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/3675
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo